Las Vegas, Nevada (N=253)

Figure A. Age of GISP participants, in years, 2012



Las Vegas, Nevada (N=253)

Figure B. Race/ethnicity of GISP participants, 2012



Las Vegas, Nevada

Figure C. Percentage of GISP participants identifying as men who have sex with men, 2000-2012



*Note: Site participated in GISP from 2002-2012.

Las Vegas, Nevada (N=253)

Figure D. Primary antibiotic used to treat gonorrhea among GISP participants, 2012



Las Vegas, Nevada (N=253)

Figure E. Secondary antibiotic used to treat gonorrhea among GISP participants, 2012



Las Vegas, Nevada (N=253)

Figure F. Resistance to penicillin, tetracycline, and ciprofloxacin among GISP isolates, 2012



Susceptible | PenR | TetR | QRNG
PenR/TetR | TetR/QRNG | PenR/TetR/QRNG

Las Vegas, Nevada

Figure G. Distribution of Minimum Inhibitory Concentrations (MICs) of ceftriaxone among GISP isolates, 2008-2012



Las Vegas, Nevada

Figure H. Distribution of Minimum Inhibitory Concentrations (MICs) of cefixime among GISP isolates, 2009-2012



NOTE: Isolates were not tested for cefixime susceptibility in 2007 and 2008.

Las Vegas, Nevada

Figure I. Intermediate resistance and resistance to ciprofloxacin among GISP isolates, 2000-2012



Note: Susceptibility to ciprofloxacin first measured in 1990. Site participated in GISP from 2002-2012.

Las Vegas, Nevada

Figure J. Distribution of Minimum Inhibitory Concentrations (MICs) of azithromycin among GISP isolates, 2008-2012